Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Rating of “Moderate Buy” by Brokerages

by · The Markets Daily

Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report) has received a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $32.00.

A number of brokerages have recently issued reports on TYRA. Wedbush restated an “outperform” rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Thursday, November 6th. Raymond James Financial began coverage on Tyra Biosciences in a report on Tuesday, September 2nd. They set a “strong-buy” rating and a $35.00 price target for the company. Wall Street Zen downgraded Tyra Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Oppenheimer reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Tyra Biosciences in a report on Wednesday, September 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a report on Wednesday, October 8th.

Check Out Our Latest Stock Analysis on Tyra Biosciences

Insider Transactions at Tyra Biosciences

In other Tyra Biosciences news, Director Robert J. More sold 246,871 shares of the stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $20.25, for a total transaction of $4,999,137.75. Following the transaction, the director owned 3,833,425 shares in the company, valued at $77,626,856.25. This represents a 6.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 15.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Tyra Biosciences

Large investors have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio increased its stake in Tyra Biosciences by 34.8% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 24,962 shares of the company’s stock worth $349,000 after acquiring an additional 6,450 shares during the period. HighVista Strategies LLC grew its holdings in shares of Tyra Biosciences by 163.6% during the 3rd quarter. HighVista Strategies LLC now owns 65,812 shares of the company’s stock worth $921,000 after purchasing an additional 40,850 shares in the last quarter. Commodore Capital LP increased its position in shares of Tyra Biosciences by 8.9% in the third quarter. Commodore Capital LP now owns 3,375,000 shares of the company’s stock worth $47,216,000 after purchasing an additional 275,000 shares during the period. Boothbay Fund Management LLC acquired a new position in Tyra Biosciences in the third quarter valued at about $2,612,000. Finally, Ameriprise Financial Inc. raised its stake in Tyra Biosciences by 8.1% in the third quarter. Ameriprise Financial Inc. now owns 87,107 shares of the company’s stock valued at $1,219,000 after purchasing an additional 6,505 shares in the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Price Performance

NASDAQ:TYRA opened at $22.11 on Friday. The company has a market cap of $1.18 billion, a P/E ratio of -11.82 and a beta of 1.09. The firm’s fifty day moving average price is $16.14 and its two-hundred day moving average price is $12.64. Tyra Biosciences has a one year low of $6.42 and a one year high of $22.83.

Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported ($0.50) EPS for the quarter, hitting the consensus estimate of ($0.50). As a group, equities research analysts expect that Tyra Biosciences will post -1.57 earnings per share for the current year.

About Tyra Biosciences

(Get Free Report)

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Featured Stories